| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTHLH |
| Uniprot No | P12272 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 37-175aa |
| 氨基酸序列 | AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEIRATSEVSPNSKPSPNTKNHPVRFGSDDEGRYLTQETNKVETYKEQPLKTPGKKKKGKPGKRKEQEKKKRRTRSAWLDSGVTGSGLEGDHLSDTSTTSLELDSR |
| 预测分子量 | 19.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTHLH重组蛋白的3篇代表性文献摘要：
---
1. **"Expression and characterization of recombinant human parathyroid hormone-related protein"**
*J.M. Moseley, M. Kubota, et al. (1987)*
首次在大肠杆菌中成功表达重组人PTHrP(PTHLH)，并通过体外实验证实其与PTH受体结合的能力，模拟天然PTH的骨吸收调节和钙代谢功能。
2. **"Parathyroid hormone-related protein in malignant hypercalcemia: Role in pathogenesis and clinical utility"**
*L.J. Suva, G.A. Rodan (1990)*
研究重组PTHrP在恶性肿瘤相关高钙血症中的作用，揭示其通过旁分泌机制促进破骨细胞活化和骨溶解，成为肿瘤微环境调控的关键因子。
3. **"Structural determinants of parathyroid hormone-related protein binding to the PTH1 receptor"**
*H. Jüppner, A.B. Abou-Samra (1994)*
通过重组PTHrP片段与PTH1受体的结合实验，阐明其N端结构域(1-34氨基酸)的α螺旋构象对受体激活的关键作用，为设计类似物提供结构基础。
---
*注：以上文献为早期经典研究，近年研究可进一步检索PubMed等数据库获取。如需特定应用方向(如骨再生、癌症治疗)的文献补充，请提供更多背景。*
PTHLH (parathyroid hormone-like hormone) recombinant protein is a biologically engineered form of the naturally occurring PTHLH protein, also known as parathyroid hormone-related protein (PTHrP). Originally identified in the 1980s for its role in humoral hypercalcemia of malignancy, PTHrP shares structural homology with parathyroid hormone (PTH), particularly in its N-terminal region, allowing it to bind and activate the PTH type 1 receptor (PTH1R). This interaction mediates diverse physiological processes, including calcium homeostasis, bone development, and cellular proliferation.
PTHrP is expressed in numerous tissues, such as bone, skin, mammary glands, and placenta, playing critical roles in embryonic development, lactation, and tissue repair. Dysregulation of PTHrP is linked to pathologies like cancer-associated hypercalcemia, osteolytic bone metastases, and skeletal dysplasia. Recombinant PTHLH proteins are typically produced using bacterial (e.g., E. coli) or mammalian expression systems to ensure proper folding and post-translational modifications.
In research, recombinant PTHLH serves as a tool to study PTH/PTHrP signaling pathways, bone metabolism, and tumor biology. Therapeutically, analogs of its N-terminal domain (e.g., teriparatide) are FDA-approved for osteoporosis treatment by promoting bone formation. Conversely, inhibitors targeting PTHrP are under investigation for cancer therapy. Its dual role in bone anabolism and catabolism, along with its involvement in cancer progression, makes PTHLH a molecule of significant clinical and pharmacological interest. Ongoing studies aim to refine its therapeutic applications and elucidate its broader biological functions.
×
